Piston Bio

New Medicine for Cancer and Autoimmune Disease

November 2026

Walter Hong, MD
Chief Executive Officer
walterhong@pistonbio.com

Pipeline

Program	Mechanism	Target Indication	Rights Status	IP	Stage
Mosperafenib	BRAF V600E inhibitor	2L+ BRAF V600E CRC	Non-binding terms agreed with Roche	Roche IP	Phase Ib completed
PST-102	Extended half-life TLR7/8 agonist	2L+ NSCLC	100% owned	Composition of matter	Pre-IND / FDA feedback received
PST-101	Extended half-life A2A antagonist	Cancer-related apathy	100% owned	Composition of matter	FDA-aligned Phase 2

Current $18M financing is dedicated exclusively to mosperafenib development.

Mosperafenib

Clinical-stage, oral BRAF inhibitor | Proposed Roche licensing opportunity

MECHANISM

Paradox-breaking BRAF inhibition

LEAD INDICATION

Previously treated BRAF V600E metastatic colorectal cancer

ADDITIONAL OPPORTUNITY

BRAF V600E melanoma


DEVELOPMENT PLAN

Proposed Phase 2 clinical evaluation

Transaction status: Agreed non-binding terms.

PST-102: Extended Half-Life TLR7/8 Agonist

1 Resiquimod / EIK1001



Given once a week

2 PST-102


DESIGNED TO EXTEND EXPOSURE

while preserving TLR7/8 pharmacologic activity



Proprietary molecular modification

3 Longer Half-Life



Given once every 3 weeks

PST-102: FDA Pre-IND Regulatory Milestone Achieved

October 5, 2026 written responses define a clear path to IND

1

Clinical Studies

Endorsed Phase 2 design and ORR primary endpoint via BICR.

2

IND-Enabling Studies

FDA defined a focused nonclinical program; toxicology reduced to one study.

3

ICH S9 Framework

Agreed 2L NSCLC qualifies for accelerated oncology development.

4

Regulatory Pathway and CMC

Confirmed 505(b)(1) regulatory pathway and endorsed CMC quality/specifications.

PST-102: Billion-Dollar Opportunity in 2L NSCLC

Unmet need: 2.6% five-year overall survival with docetaxel

Total Addressable Market:

Global NSCLC therapeutics

$20-30 billion

Serviceable Addressable Market:

~150K-220K 2L NSCLC patients annually (US + EU)

$3-6 billion

Serviceable Obtainable Market:

20–30% share of 2L NSCLC market

Peak sales: $1 billion +

PST-101: FDA Alignment Establishes Phase 2 Path

- Type B Pre-IND meeting completed with FDA
- FDA alignment established key elements of the proposed Phase 2 clinical development strategy for the parent A2A receptor antagonist program in cancer-related apathy.
  - Randomized, placebo-controlled study
  - NSCLC
  - Primary endpoint: AES-C
- PST-101 has since evolved into a proprietary next-generation A2A receptor antagonist protected by composition-of-matter intellectual property.
- The FDA-aligned clinical development strategy provides a strong regulatory foundation for advancing next-generation PST-101

Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Research. 1991;38:143–162.

World-Class Leadership & Advisors



Walter Hong, MD
Founder and CEO, Piston Bio
20+ Years of Clinical Development Experience



Antoni Ribas, MD, PhD
UCLA – Tumor Immunology



Adil Daud, MD
UCSF – Melanoma Clinical Research



Matthew Zibelman, MD
Fox Chase Cancer Center – Genitourinary Research

Why Piston Bio

- Mosperafenib: Non-binding licensing terms agreed with Roche for a clinical-stage BRAF V600E inhibitor
- PST-102: FDA Pre-IND written responses received October 5, 2026
- PST-101: FDA-aligned Phase 2 development strategy for cancer-related apathy
- Proprietary IP: Composition-of-matter patent applications for PST-101 and PST-102
- Capital-efficient strategy: Combining internally developed medicines with clinical-stage in-licensing opportunities